HIKAL234.10

Hikal Limited

· Pharma & Health
₹ CrorePeersPANACEABIODCALSAIPARENTINDOCOSOLARAWINDLASINDSWFTLABHESTERBIOMcap ₹2,891 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt814.7762.3681.1681.1
Net Debt802.0749.3671.5671.5
Total Debt/Equity0.690.600.570.57
Net Debt/Equity0.680.590.560.56
Total Debt/EBITDA3.052.323.093.09
Net Debt/EBITDA3.002.283.052.89
Interest Coverage (EBIT/Interest)2.652.580.910.91
Total Debt/Total Capital %40.6937.6536.2336.23
As Filed — company-reported covenants
Debt/Equity (as filed)0.590.560.53
Debt Service Coverage (as filed)1.451.221.23
Interest Service Coverage (as filed)4.003.763.82
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.